-
The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) StudyIbrahim NE, Januzzi JL Jr. -
Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF TrialMN Kosiborod, PJhund, KF Docherty et al.
-
2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm SocietyKusumoto FM, Schoenfeld MH, Barrett C et al.
-
A Fully Magnetically Levitated Left Ventricular Assist Device — Final ReportMR Mehra, N Uriel, MOMENTUM 3 Investigators.
-
Impact of Myocardial Scar on Prognostic Implication of Secondary Mitral Regurgitation in Heart FailureB Tayal, D Debs, F Nabi et al.
-
In acute HF and iron deficiency, IV ferric carboxymaltose reduced HF hospitalizations, but not CV death, at 1 yEM DeFilippis, HGC Van Spall.
-
Positive recommendation for angiotensin receptor/neprilysin inhibitor: First medication approval for heart failure without "reduced ejection fraction"JG Howlett.
-
Sex Differences in Cardiovascular Pathophysiology: Why Women Are Overrepresented in Heart Failure With Preserved Ejection FractionBeale AL, Meyer P, Kaye DM et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
